Model TCB002 - Unmodified Allogeneic GDTs

TCB002 is an unmodified allogeneic gamma delta T cell product, being initially used for the treatment of Acute Myeloid Leukaemia (AML). This product is currently undergoing a phase 1 clinical trial as part of a dose escalation and safety study, in partnership with ÚKHT, Institute of Hematology and Blood Transfusion, Prague. AML is a cancer characterized by infiltration of the bone marrow, blood, and other tissues by proliferative, clonal, poorly differentiated cells of the hematopoietic system.